Co-delivery of doxorubicin and siRNA using octreotide-conjugated gold nanorods for targeted neuroendocrine cancer therapy.
Co-delivery of doxorubicin and siRNA using octreotide-conjugated gold nanorods for targeted neuroendocrine cancer therapy.
复制标题
DOI：
10.1039/c2nr31853a
复制
发表时间：
2012-11-21
期刊：
影响因子：
6.7
通讯作者：
Gong S
中科院分区：
文献类型：
--
作者：
Xiao Y;Jaskula-Sztul R;Javadi A;Xu W;Eide J;Dammalapati A;Kunnimalaiyaan M;Chen H;Gong S
A multifunctional gold (Au) nanorod (NR)-based nanocarrier capable of co-delivering small interfering RNA (siRNA) against achaete-scute complex-like 1 (ASCL1) and an anticancer drug (doxorubicin (DOX)) specifically to neuroendocrine (NE) cancer cells was developed and characterized for combined chemotherapy and siRNA-mediated gene silencing. The Au NR was conjugated with (1) DOX, an anticancer drug, via a pH-labile hydrazone linkage to enable pH-controlled drug release, (2) polyarginine, a cationic polymer for complexing siRNA, and (3) octreotide (OCT), a tumor-targeting ligand, to specifically target NE cancer cells with overexpressed somatostatin receptors. The Au NR-based nanocarriers exhibited a uniform size distribution as well as pH-sensitive drug release. The OCT-conjugated Au NR-based nanocarriers (Au-DOX-OCT, targeted) exhibited a much higher cellular uptake in a human carcinoid cell line (BON cells) than non-targeted Au NR-based nanocarriers (Au-DOX) as measured by both flow cytometry and confocal laser scanning microscopy (CLSM). Moreover, Au-DOX-OCT-ASCL1 siRNA (Au-DOX-OCT complexed with ASCL1 siRNA) resulted in significantly higher gene silencing in NE cancer cells than Au-DOX-ASCL1 siRNA (non-targeted Au-DOX complexed with ASCL1 siRNA) as measured by an immunoblot analysis. Additionally, Au-DOX-OCT-ASCL1 siRNA was the most efficient nanocarrier at altering the NE phenotype of NE cancer cells and showed the strongest anti-proliferative effect. Thus, combined chemotherapy and RNA silencing using NE tumor-targeting Au NR-based nanocarriers could potentially enhance the therapeutic outcomes in treating NE cancers.
登录
查看更多内容
影响因子：
13.3
作者：
Chen, Alex M.;Zhang, Min;Wei, Dongguang;Stueber, Dirk;Taratula, Oleh;Minko, Tamara;He, Huixin
通讯作者：
He, Huixin
影响因子：
6.7
作者：
Choi KY;Liu G;Lee S;Chen X
通讯作者：
Chen X
影响因子：
16.6
作者：
Lee, Jae-Hyun;Lee, Kyuri;Cheon, Jinwoo
通讯作者：
Cheon, Jinwoo
影响因子：
5.2
作者：
Chen, H;Hardacre, JM;Choti, MA
通讯作者：
Choti, MA
影响因子：
1.8
作者：
Fiorentini, G;Rossi, S;Guadagni, S
通讯作者：
Guadagni, S